Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G. Razis E, et al. Among authors: bafaloukos d. Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19. Breast Cancer Res Treat. 2011. PMID: 21594665 Free article.
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP. Fountzilas G, et al. Among authors: bafaloukos d. Breast Cancer Res Treat. 2009 May;115(1):87-99. doi: 10.1007/s10549-008-0047-9. Epub 2008 May 16. Breast Cancer Res Treat. 2009. PMID: 18483853 Clinical Trial.
Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab.
Economopoulou P, Kotoula V, Koliou GA, Papadopoulou K, Christodoulou C, Pentheroudakis G, Lazaridis G, Arapantoni-Dadioti P, Koutras A, Bafaloukos D, Papakostas P, Patsea H, Pavlakis K, Pectasides D, Kotsakis A, Razis E, Aravantinos G, Samantas E, Kalogeras KT, Economopoulos T, Psyrri A, Fountzilas G. Economopoulou P, et al. Among authors: bafaloukos d. Transl Oncol. 2019 May;12(5):739-748. doi: 10.1016/j.tranon.2019.02.010. Epub 2019 Mar 14. Transl Oncol. 2019. PMID: 30877976 Free PMC article.
Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.
Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, Christodoulou CH, Timotheadou E, Kalofonos CH, Kosmidis P, Adamou A, Papakostas P, Gogas H, Stathopoulos G, Razis E, Bafaloukos D, Skarlos D. Fountzilas G, et al. Among authors: bafaloukos d. Ann Oncol. 2001 Nov;12(11):1545-51. doi: 10.1023/a:1013184301155. Ann Oncol. 2001. PMID: 11822753 Free article. Clinical Trial.
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos LA, Economopoulos T, Pectasides D, Maniadakis N, Siafaka V, Briasoulis E, Christodoulou C, Tsavdaridis D, Makrantonakis P, Razis E, Kosmidis P, Skarlos D, Dimopoulos MA. Fountzilas G, et al. Among authors: bafaloukos d. Ann Oncol. 2004 Oct;15(10):1517-26. doi: 10.1093/annonc/mdh395. Ann Oncol. 2004. PMID: 15367413 Free article. Clinical Trial.
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group.
Bafaloukos D, Papadimitriou C, Linardou H, Aravantinos G, Papakostas P, Skarlos D, Kosmidis P, Fountzilas G, Gogas H, Kalofonos C, Dimopoulos AM. Bafaloukos D, et al. Br J Cancer. 2004 Nov 1;91(9):1639-44. doi: 10.1038/sj.bjc.6602148. Br J Cancer. 2004. PMID: 15494721 Free PMC article. Clinical Trial.
Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H, Bafaloukos D, Aravantinos G, Fountzilas G, Tsoutsos D, Panagiotou P, Frangia K, Kalofonos HP, Briasoulis E, Castana O, Polyzos A, Pectasides D, Ioannovich J; Hellenic Cooperative Oncology Group. Gogas H, et al. Among authors: bafaloukos d. Cancer Invest. 2004;22(6):832-9. doi: 10.1081/cnv-200039630. Cancer Invest. 2004. PMID: 15641480 Clinical Trial.
Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.
Onyenadum A, Gogas H, Kosmidis P, Aravantinos G, Bafaloukos D, Bacoyiannis H, Markopoulos C, Koutras A, Tzorakoelefterakis E, Makatsoris T, Fountzilas G, Kalofonos HP; Hellenic Cooperative Oncology Group. Onyenadum A, et al. Among authors: bafaloukos d. J Chemother. 2006 Apr;18(2):192-8. doi: 10.1179/joc.2006.18.2.192. J Chemother. 2006. PMID: 16736889 Clinical Trial.
Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
Onyenadum A, Gogas H, Markopoulos C, Bafaloukos D, Aravantinos G, Mantzourani M, Koutras A, Tzorakoelefterakis E, Xiros N, Makatsoris T, Fountzilas G, Kalofonos HP. Onyenadum A, et al. Among authors: bafaloukos d. J Chemother. 2007 Oct;19(5):582-9. doi: 10.1179/joc.2007.19.5.582. J Chemother. 2007. PMID: 18073159 Clinical Trial.
195 results